Clinical trial · Interventional
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)
NCT00482014CI-TRIAL-00008537completedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| cisplatin | Drug | Cisplatin | ALIAS |
| pemetrexed | Drug | Pemetrexed | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A: Pemetrexed + Carboplatin
- description
- Pemetrexed + Carboplatin
- interventionNames
- Drug: pemetrexed
- Drug: carboplatin
- Radiation: radiation therapy
- type
- EXPERIMENTAL
- label
- B: Pemetrexed + Cisplatin
- description
- Pemetrexed + Cisplatin
- interventionNames
- Drug: pemetrexed
- Drug: cisplatin
- Radiation: radiation therapy
Primary outcomes (3)
- measure
- Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Inoperable non small cell lung cancer * No weight loss greater than 10% in 3 months prior to enrolling in trial * Adequate kidney function * Adequate liver function * Adequate lung function Exclusion Criteria: * Previous surgery to remove lung tumor * Previous chemotherapy or radiation therapy or lung cancer * Inability to take vitamin supplementation * Heart attack within past 6 months * Active infection
References
Publications (0)
Data not yet available
No reference posted for this study.